WST Relative Valuation
WST's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, WST is overvalued; if below, it's undervalued.
Historical Valuation
West Pharmaceutical Services Inc (WST) is now in the Undervalued zone, suggesting that its current forward PE ratio of 38.11 is considered Undervalued compared with the five-year average of 42.57. The fair price of West Pharmaceutical Services Inc (WST) is between 285.93 to 373.97 according to relative valuation methord. Compared to the current price of 284.31 USD , West Pharmaceutical Services Inc is Undervalued By 0.57%.
Relative Value
Fair Zone
285.93-373.97
Current Price：284.31
0.57%
Undervalued
37.77
PE
1Y
3Y
5Y
Trailing
Forward
24.18
EV/EBITDA
West Pharmaceutical Services Inc. (WST) has a current EV/EBITDA of 24.18. The 5-year average EV/EBITDA is 28.03. The thresholds are as follows: Strongly Undervalued below 18.12, Undervalued between 18.12 and 23.07, Fairly Valued between 32.98 and 23.07, Overvalued between 32.98 and 37.94, and Strongly Overvalued above 37.94. The current Forward EV/EBITDA of 24.18 falls within the Historic Trend Line -Fairly Valued range.
30.62
EV/EBIT
West Pharmaceutical Services Inc. (WST) has a current EV/EBIT of 30.62. The 5-year average EV/EBIT is 34.03. The thresholds are as follows: Strongly Undervalued below 21.89, Undervalued between 21.89 and 27.96, Fairly Valued between 40.09 and 27.96, Overvalued between 40.09 and 46.16, and Strongly Overvalued above 46.16. The current Forward EV/EBIT of 30.62 falls within the Historic Trend Line -Fairly Valued range.
6.38
PS
West Pharmaceutical Services Inc. (WST) has a current PS of 6.38. The 5-year average PS is 8.02. The thresholds are as follows: Strongly Undervalued below 4.82, Undervalued between 4.82 and 6.42, Fairly Valued between 9.62 and 6.42, Overvalued between 9.62 and 11.21, and Strongly Overvalued above 11.21. The current Forward PS of 6.38 falls within the Undervalued range.
28.71
P/OCF
West Pharmaceutical Services Inc. (WST) has a current P/OCF of 28.71. The 5-year average P/OCF is 34.97. The thresholds are as follows: Strongly Undervalued below 22.22, Undervalued between 22.22 and 28.59, Fairly Valued between 41.34 and 28.59, Overvalued between 41.34 and 47.72, and Strongly Overvalued above 47.72. The current Forward P/OCF of 28.71 falls within the Historic Trend Line -Fairly Valued range.
46.52
P/FCF
West Pharmaceutical Services Inc. (WST) has a current P/FCF of 46.52. The 5-year average P/FCF is 65.28. The thresholds are as follows: Strongly Undervalued below 30.27, Undervalued between 30.27 and 47.77, Fairly Valued between 82.79 and 47.77, Overvalued between 82.79 and 100.29, and Strongly Overvalued above 100.29. The current Forward P/FCF of 46.52 falls within the Undervalued range.
West Pharmaceutical Services Inc (WST) has a current Price-to-Book (P/B) ratio of 6.70. Compared to its 3-year average P/B ratio of 8.27 , the current P/B ratio is approximately -19.00% higher. Relative to its 5-year average P/B ratio of 9.73, the current P/B ratio is about -31.18% higher. West Pharmaceutical Services Inc (WST) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 1.67%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 1.56% , the current FCF yield is about -100.00% lower.
6.64
P/B
Median3y
8.27
Median5y
9.73
1.85
FCF Yield
Median3y
1.67
Median5y
1.56
Competitors Valuation Multiple
The average P/S ratio for WST's competitors is 1.31, providing a benchmark for relative valuation. West Pharmaceutical Services Inc Corp (WST) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 7.73%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of WST decreased by 13.98% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 746.90M to 804.60M.
The secondary factor is the Margin Expansion, contributed -4.45%to the performance.
Overall, the performance of WST in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is West Pharmaceutical Services Inc (WST) currently overvalued or undervalued?
What is West Pharmaceutical Services Inc (WST) fair value?
How does WST's valuation metrics compare to the industry average?
What is the current P/B ratio for West Pharmaceutical Services Inc (WST) as of Dec 05 2025?
What is the current FCF Yield for West Pharmaceutical Services Inc (WST) as of Dec 05 2025?
What is the current Forward P/E ratio for West Pharmaceutical Services Inc (WST) as of Dec 05 2025?